Management of belantamab mafodotin-associated corneal events in patients with relapsed or refractory multiple myeloma (RRMM)

Belantamab mafodotin (belamaf) demonstrated deep and durable responses in patients with heavily pretreated relapsed or refractory multiple myeloma (RRMM) in DREAMM-2 (NCT03525678). Corneal events, specifically keratopathy (including superficial punctate keratopathy and/or microcyst-like epithelial c...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Blood Cancer J
Päätekijät: Lonial, Sagar, Nooka, Ajay K., Thulasi, Praneetha, Badros, Ashraf Z., Jeng, Bennie H., Callander, Natalie S., Potter, Heather A., Sborov, Douglas, Zaugg, Brian E., Popat, Rakesh, Degli Esposti, Simona, Byrne, Julie, Opalinska, Joanna, Baron, January, Piontek, Trisha, Gupta, Ira, Dana, Reza, Farooq, Asim V., Colby, Kathryn, Jakubowiak, Andrzej
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Nature Publishing Group UK 2021
Aiheet:
Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC8155129/
https://ncbi.nlm.nih.gov/pubmed/34039952
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41408-021-00494-4
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia